MO10-6 miR-4647 an early biomarker of outcome in chronic myeloid leukaemia patients

A significant number of CML patients relapse after discontinuation of therapy, even after achieving DMR, which calls for a need of early biomarkers to discontinue therapy. miRs have a vital role in pathways that decide the pharmacokinetics and pharmacodynamics displayed by a particular patient. Therefore, in this study, we studied the role of miRs to achieve DMR by CML patients on imatinib therapy.